SYRS - サイロス・ファ―マシュ―ティカルズ （Syros Pharmaceuticals Inc.） サイロス・ファ―マシュ―ティカルズSYRSのチャート
SYRSの企業情報
| symbol | SYRS |
|---|---|
| 会社名 | Syros Pharmaceuticals Inc （サイロス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 シロス・ファーマーセウティカルズ(Syros Pharmaceuticals Inc.)はバイオ医薬品会社である。同社はヒト疾病組織における未知のデオキシリボ核酸（DNA）の領域を分析し、ゲノム的に定義された患者集団に関連する標的を同定し、薬物を創出するように設計された遺伝子制御プラットフォームを提供する。同社はがんおよび免疫媒介疾患の治療法の開発に注力し、遺伝子制御薬のパイプラインを構築している。同社の薬物プログラムには、SY-1425（レチノイン酸受容体アルファ（RARa）アゴニスト）およびSY-1365（サイクリン依存性キナーゼ7（CDK7）阻害剤）が含まれる。SY-1425（タミバロチン）は、転写因子RARaの経口の強力で選択的なアゴニストまたは活性化剤である。SY-1365は、CDK7として知られた転写キナーゼの小分子阻害剤である。同社はそのプラットフォームを使用して、追加の癌、炎症性疾患および他の疾患にわたって遺伝子発現プログラムを分析し、患者の特定のサブセットにおける治療的介入の最適点を同定する。 サイロス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主として、遺伝子の起動や抑制をコントロ―ルするゲノム制御分野に基づき、ガンや免疫性疾患の治療薬の開発、製造を行う。同社の遺伝子制御プラットフォ―ムは、ゲノム的定義に関連した新たな遺伝子制御の特定や遺伝子制御を麻痺させることを目的とする。本社はマサチュ―セッツ州ケンブリッジ。 syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs. |
| 本社所在地 | 620 Memorial Drive Suite 300 Cambridge MA 02139 USA |
| 代表者氏名 | Peter Wirth ピーター・ワース |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-744-1340 |
| 設立年月日 | 40848 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 56人 |
| url | www.syros.com |
| nasdaq_url | https://www.nasdaq.com/symbol/syrs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -57.38400 |
| 終値（lastsale） | 8.26 |
| 時価総額（marketcap） | 277985253.14 |
| 時価総額 | 時価総額（百万ドル） 239.28270 |
| 売上高 | 売上高（百万ドル） 0.74500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 114.95270 |
| 当期純利益 | 当期純利益（百万ドル） -57.63700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Syros Pharmaceuticals Inc revenues decreased 32% to $745K. Net loss increased 15% to $28.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 11% to $21M (expense) Stock-based Compensation in SGA increase of 75% to $2.2M (expense). |
SYRSのテクニカル分析
SYRSのニュース
Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 2023/05/25 21:09:03 Investing.com
https://www.investing.com/news/assorted/syros-pharmaceuticals-presents-data-from-phase-11b-clinical-trial-of-sy5609-432SI-3091409
Syros Pharmaceuticals (SYRS) Investor Presentation - Slideshow 2023/05/18 15:24:29 Seeking Alpha
The following slide deck was published by Syros Pharmaceuticals, Inc.
JMP Securities maintains Syros Pharma at ''market outperform'' with a price target of $15.00 2023/05/11 07:05:45 Investing.com
https://www.investing.com/news/pro/syros-pharmaceuticals-inc-receives-investment-bank-analyst-rating-update-3079550
Syros Pharmaceuticals, Inc. (SYRS) Q1 2023 Earnings Call Transcript 2023/05/11 02:12:05 Seeking Alpha
Syros Pharmaceuticals, Inc. (NASDAQ:NASDAQ:SYRS) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ETCompany ParticipantsKaren Hunady - Director, Investor Relations and Corporate…
Earnings Scheduled For May 10, 2023 2023/05/10 13:12:28 Benzinga
Companies Reporting Before The Bell • Nomad Foods (NYSE: NOMD ) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million. • Banco Latinoamericano (NYSE: BLX ) is likely to report quarterly earnings at $0.42 per share on revenue of $263.98 million. • Beauty Health (NASDAQ: SKIN ) is likely to report quarterly loss at $0.02 per share on revenue of $90.37 million. • Vishay Intertechnology (NYSE: VSH ) is projected to report quarterly earnings at $0.55 per share on revenue of $845.80 million. • Bragg Gaming Group (NASDAQ: BRAG ) is estimated to report quarterly loss at $0.05 per share on revenue of $32.00 million. • Ballard Power Systems (NASDAQ: BLDP ) is projected to report quarterly loss at $0.13 per share on revenue of $24.08 million. • ProFrac Holding (NASDAQ: ACDC ) is estimated to report quarterly earnings at $0.80 per share on revenue of $893.04 million. • Roblox (NYSE: RBLX ) is projected to report quarterly loss at $0.40 per share on revenue of $765.
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 2023/05/03 11:30:00 Wallstreet:Online
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update. To access the live conference call,
Myelodysplastic Syndrome Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - Fibrogen, Abbvie, Gilead Sciences, Novartis, Syros Pharma, Geron Corporation, Karyopharm, Antengene Corporation 2023/04/13 10:58:59 OpenPR
DelveInsight''s "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and
Syros Pharmaceuticals files for $250M mixed shelf offering - filing 2023/04/06 20:23:10 Seeking Alpha
Syros Pharmaceuticals (SYRS) on Thursday disclosed in an SEC filing a prospectus for a proposed mixed shelf offering to raise $250 million.
Tesla To Rally Around 15%? Here Are 10 Other Analyst Forecasts For Friday 2023/03/03 13:16:37 Benzinga
Credit Suisse cut the price target for Hormel Foods Corporation (NYSE: HRL ) from $44 to $41. Credit Suisse analyst Robert Moskow maintained a Neutral rating. Hormel Foods shares fell 1.7% to $41.13 in pre-market trading. Truist Securities boosted the price target for Broadcom Inc. (NASDAQ: AVGO ) from $659 to $700. Truist Securities analyst William Stein maintained a Buy rating on the stock. Broadcom shares rose 0.9% to close at $598.65 on Thursday. Raymond James raised the price target for Integral Ad Science Holding Corp. (NASDAQ: IAS ) from $12 to $17. Raymond James analyst Andrew Marok maintained a Strong Buy rating. Integral Ad Science shares gained 2% to close at $10.70 on Thursday. Oppenheimer cut Syros Pharmaceuticals, Inc. (NASDAQ: … Full story available on Benzinga.com
Syros Pharmaceuticals PT Lowered to $13 at Oppenheimer 2023/03/02 21:29:01 Investing.com
https://www.investing.com/news/pro/syros-pharmaceuticals-pt-lowered-to-13-at-oppenheimer-432SI-3020940
Myelodysplastic Syndrome Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - Fibrogen, Abbvie, Gilead Sciences, Novartis, Syros Pharma, Geron Corporation, Karyopharm, Antengene Corporation 2023/04/13 10:58:59 OpenPR
DelveInsight''s "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and
Syros Pharmaceuticals files for $250M mixed shelf offering - filing 2023/04/06 20:23:10 Seeking Alpha
Syros Pharmaceuticals (SYRS) on Thursday disclosed in an SEC filing a prospectus for a proposed mixed shelf offering to raise $250 million.
Tesla To Rally Around 15%? Here Are 10 Other Analyst Forecasts For Friday 2023/03/03 13:16:37 Benzinga
Credit Suisse cut the price target for Hormel Foods Corporation (NYSE: HRL ) from $44 to $41. Credit Suisse analyst Robert Moskow maintained a Neutral rating. Hormel Foods shares fell 1.7% to $41.13 in pre-market trading. Truist Securities boosted the price target for Broadcom Inc. (NASDAQ: AVGO ) from $659 to $700. Truist Securities analyst William Stein maintained a Buy rating on the stock. Broadcom shares rose 0.9% to close at $598.65 on Thursday. Raymond James raised the price target for Integral Ad Science Holding Corp. (NASDAQ: IAS ) from $12 to $17. Raymond James analyst Andrew Marok maintained a Strong Buy rating. Integral Ad Science shares gained 2% to close at $10.70 on Thursday. Oppenheimer cut Syros Pharmaceuticals, Inc. (NASDAQ: … Full story available on Benzinga.com